b.next is building the ecosystem, technology, and infrastructure to deploy synthetic cells against the world's hardest problems. Since launching in June 2023, b.next has grown a global community of academic, industry, and government researchers building synthetic cells together. We built and maintain Nucleus, an open platform for synthetic cell engineering, operate a manufacturing plant producing the physical materials researchers need to build on it, and advance R&D programs that push new synthetic cell capabilities from the lab into the world.
| Website | https://bnext.bio |
| Employees | 13 (11 on RocketReach) |
| Founded | 2023 |
| Industry | Biotechnology Research |
| Keywords | Biotech, Synthetic Biology, Biotechnology Innovation, Bioengineering, Biotechnology, Engineering Biology, Genetic Engineering, Biomanufacturing, Biotechnology Research, Biological Engineering, Cellular Engineering, Molecular Engineering, Biomedical Engineering, Genome Engineering, Protein Engineering, Metabolic Engineering, Tissue Engineering, Bioprocess Development |
| Competitors | Novartis, AstraZeneca, Amgen, Regeneron, Illumina, Biogen, Moderna Therapeutics, Zymeworks Inc., Zymergen, Inc., CARB-X +39 more (view full list) |
Looking for a particular b.next employee's phone or email?
Akshay Maheshwari is the Co-Founder and CEO of b.next.
11 people are employed at b.next.